Skye accuses Spectral of allegedly running a spoiling campaign to scupper IPO (initial public offering)
This article was originally published in Clinica
Canadian diagnostics company Skye Pharmatech has filed suit in an Ontario court, claiming that an alleged campaign orchestrated by some of the board of directors of a rival Canadian diagnostic company, Spectral Diagnostics, derailed Skye's initial public offering (IPO) in March. The IPO achieved less than a third of its expected sum - raising just Can+ACQ-1.8 million rather than the predicted Can+ACQ-6.5 million. Spectral has vehemently denied the claim and says that it will fight the lawsuit vigorously.
You may also be interested in...
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.